Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2096 results about "Inhibitory effect" patented technology

An inhibitory effect is an effect that suppresses or restrains an impulse, a desire or a behavioral process either consciously or unconsciously. In science, the term is used to mean the prevention or decrease the rate of a chemical reaction or to decrease, limit or block a bodily action or function such as that of an enzyme or organ.

Nitrogen-containing heterocyclic compound, pharmaceutical composition thereof and application thereof

Disclosed is a nitrogen-containing heterocyclic compound, pharmaceutical composition thereof and application thereof. The present disclosure provides a nitrogen-containing heterocyclic compound of formula I, a pharmaceutically acceptable salt thereof, a prodrug thereof, a stereoisomer thereof, a tautomer thereof or an isotopically labeled compound thereof. The nitrogen-containing heterocyclic compounds as represented in Formula I in the present disclosure have good inhibitory effects on cells of various mutations such as KRAS G12C, KRAS G12D, KRAS G12V, KRAS Q61H and other mutations, as well as on KRAS-amplified wild-type cells, and are expected to treat and / or prevent a wide range of diseases associated with Ras.
Owner:YINGLI PHARMA (BVI) LTD

KRASG12D-targeted substituted quinolinone compound and application thereof

The invention relates to the field of medicinal chemistry, in particular to a substituted quinolinone compound targeting KRASG12D and application of the substituted quinolinone compound. Pharmacological tests prove that the affinity effect of the synthesized compound on a KRASG12D mutant is superior to that of a lead compound KAL-21404358. The compounds WY1-014 and WY1-062 have ideal inhibition effects on cells of human lung cancer (A549), human melanoma (A375) and human colon cancer (LOVO). The compound WY1-062 has excellent anti-tumor activity, and the activity of the compound WY1-062 is superior to that of cis-platinum.
Owner:SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI

Purple KRAS inhibitor and medical application thereof

The invention relates to the field of medicinal chemistry, relates to a general KRAS inhibitor and medical application thereof, and particularly relates to a compound targeting KRAS and mutants KRASG12C and KRASG12D thereof and medical application of the compound. The pharmacological test result of the affinity of KRAS and mutants thereof shows that the affinity of the compound to a KRAS wild type and a KRASG12C mutant type thereof and a KRASG12D mutant type thereof is superior to that of a lead compound, and the compound has a potential inhibition effect on target spots of the KRAS wild type and the KRASG12C mutant type thereof and the KRASG12D mutant type thereof.
Owner:SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI

Hydroxyl-substituted dihydroisoquinolinone compound as well as preparation method and application thereof

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a hydroxyl-substituted dihydroisoquinolinone compound. The compound has a good KRAS G12V mutant gene inhibition effect, and can be used for treating tumor diseases related to KRAS G12V gene mutation.
Owner:SHANGHAI QILU PHARMACEUTICAL RESEARCH & DEVELOPMENT CENTRE LTD

Pyrimidine macrocyclic KRAS inhibitor

The present invention belongs to the technical field of medicinal chemistry, and particularly relates to a pyrimidine macrocyclic compound. The compound has a good inhibitory effect on KRAS mutations, has a good inhibitory effect on the G12V mutation and other types of mutations of the KRAS gene, can be used as a general KRAS inhibitor, and can be used for the treatment of tumors driven by KRASG12V and other types of gene mutations.
Owner:SHANGHAI QILU PHARMACEUTICAL RESEARCH & DEVELOPMENT CENTRE LTD

Pan-ras inhibitor compound

The present invention relates to a compound as shown in formula (A) having a pan-RAS inhibitory effect, or an isotopic derivative or stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the compound, and the use of the compound of formula (A) in the prevention and / or treatment of cancers, tumors, inflammatory diseases, autoimmune diseases or immune-mediated diseases.
Owner:ADLAI NORTYE BIOPHARMA CO LTD

Lactobacillus paracasei JNL0025 and application thereof

The invention belongs to the technical field of microorganisms, and relates to a lactobacillus paracasei JNL0025 strain and application thereof. Compared with a commercial strain lactobacillus casei substitute strain, the lactobacillus paracasei JNL0025 provided by the invention has the advantages that the guanine nucleoside conversion rate is improved, the inhibition rate of supernate on XOD is equivalent, and the inhibition on PNP activity can be realized; according to the lactobacillus paracasei JNL0025 disclosed by the invention, the lactobacillus paracasei JNL0025 has the effects of reducing the tendency of pro-inflammatory M1 type macrophages, increasing the proportion of anti-inflammatory M2 type macrophages and inhibiting secretion of pro-inflammatory cytokines TNF-alpha and IL-6, and the lactobacillus paracasei JNL0025 has a better inflammation inhibition effect than the lactobacillus rhamnosus LGG; animal experiment results show that the lactobacillus paracasei JNL0025 provided by the invention can significantly reduce the blood uric acid level of a hyperuricemia model mouse, alleviate the kidney inflammation level and alleviate DSS-induced colitis, and shows a huge application value.
Owner:JINAN MICROECOLOGY & BIOMEDICINE PROVINCIAL LAB

Compound as LPAR1 antagonist, pharmaceutical composition thereof and use thereof

A compound as an LPAR1 antagonist, a pharmaceutical composition thereof and a use thereof. A compound represented by formula (I), as well as a racemate, stereoisomer, tautomer, nitrogen oxide, or pharmaceutically acceptable salt thereof. The compound of the LPAR1 antagonist has a good inhibitory effect on LPAR1, has excellent pharmacokinetic properties, and has good druggability.
Owner:WUHAN LL SCI & TECH DEV CO LTD

Bullfrog skin peptide with DPP-IV (dipeptidyl peptidase-IV) inhibitory activity as well as purification method and application thereof

The invention discloses bullfrog skin peptide with DPP-IV inhibitory activity and a purification method and application thereof.The molecular weight of the bullfrog skin peptide is 681.40 Da, and the amino acid sequence of the bullfrog skin peptide is shown as SEQ ID NO.1. The bullfrog skin peptide is extracted through an enzymolysis means, then components containing peptide fragments are extracted through a column chromatography purification mode, finally the components are evaluated and screened, and the bullfrog skin peptide with the DPP-IV inhibitory activity is obtained. The purified bullfrog skin peptide with the DPP-IV inhibitory activity is obtained. The bullfrog skin peptide with the DPP-IV inhibitory activity has the advantages of being strong in DPP-IV enzyme inhibitory effect, safe and free of toxic and side effects, has the application potential of hypoglycemic peptides, is short in amino acid sequence and strong in operability, and has good social popularization and application value.
Owner:化学与精细化工广东省实验室潮州分中心

Application of novel nano drug-loading delivery system of exosome-loaded ginsenoside Rh2

PendingCN119280413Aprevent fibrosissuppressed expression levelOrganic active ingredientsPharmaceutical non-active ingredientsBiotechnologyCD86
The invention is applicable to the technical field of biological pharmacy, and provides application of a novel nano drug-loading delivery system of exosome-loaded ginsenoside Rh2. The ginsenoside Rh2 and the MSC-derived exosome are subjected to blending ultrasonic treatment to realize exosome drug loading, and a novel Rh2-coated MSC-exo nano drug loading delivery system is synthesized. Animal experiments show that the Rh2 (at) MSC-exo novel nano drug-loading delivery system can be targeted to ectopic intimal lesions and has an inhibition effect; the expression level of an M1 type macrophage marker CD86 is enhanced, and the expression level of an M2 type macrophage marker CD206 is inhibited; the m6A level and the METTL3 expression level of ectopic endometrial tissues are reduced; according to the present invention, RNA-seq and MIP-seq sequencing is adopted to determine that WNT2 is the potential target of the Rh2 (at) MSC-exo novel nanometer drug loading delivery system affecting ectopic inner membrane m6A modification;
Owner:JILIN UNIVERSITY

Gentiopicroside amide derivative, synthetic method and application

The invention belongs to the technical field of organic chemical synthesis, and particularly relates to a gentiopicroside amide derivative, a synthesis method and application. A series of gentiopicroside amide derivatives are synthesized by taking gentiopicroside as a research object, carrying out structural modification on 6 '-site hydroxyl of gentiopicroside and introducing a benzoyl chloride group into a gentiopicroside structure. The synthetic method has the beneficial effects that on one hand, the synthetic method of the gentiopicroside amide derivative, which is mild in reaction condition and environment-friendly, is established; on the other hand, the 20 synthesized gentiopicroside amide derivatives have a remarkable inhibition effect on expression of LPS-induced THP-1 macrophage IL-6 and STAT3 protein content, the anti-inflammatory activity is remarkable, the action effect is superior to that of parent compound gentiopicroside, and a new thought is provided for preparation of STAT3 small-molecule inhibitors and anti-inflammatory drugs.
Owner:GANSU UNIV OF CHINESE MEDICINE

Fused tricyclic compound, and preparation method therefor and use thereof

The present invention relates to a fused tricyclic compound, and a preparation method therefor and a use thereof. The compound has a structure shown in a formula (I), has an SARM1 inhibition effect, and can be used for treating neurodegenerative diseases.
Owner:SHENZHEN ZHONGGE BIOLOGICAL TECH CO LTD

Nocardia seriolae bacteriophage as well as composition and application thereof

The invention relates to the technical field of microorganisms, in particular to nocardia seriolae bacteriophage as well as a composition and application thereof. The name of the nocardia seriolae bacteriophage is RDP-NS002, the nocardia seriolae bacteriophage is preserved in the China General Microbiological Culture Collection Center on August 25, 2025, and the preservation number of the nocardia seriolae bacteriophage is CGMCC No.46674. The nocardia seriolae bacteriophage is named as RDP-NS002, and the nocardia seriolae bacteriophage is preserved in the China General Microbiological Culture Collection Center on August 25, 2025. The composition comprises the bacteriophage. The bacteriophage or the composition is prepared in the following steps: (1) preparing a product for killing nocardia seriolae; (2) preparing a product for inhibiting nocardia seriola; and (3) application in preparation of a product for preventing and / or treating fish nocardia disease caused by nocardia seriolae. The phage has the characteristics of high thermal stability, high acid-base stability and high splitting rate, has a long-acting inhibition effect, and is beneficial to prevention and treatment of nocardia seriola diseases.
Owner:QINGDAO RUNDA BIOTECH

Compounds having PTPN2 inhibitory effects and use thereof

Disclosed are compounds having PTPN2 inhibitory effects and a use thereof. Specifically, disclosed are a class of compounds having protein tyrosine phosphatase inhibitory effects or pharmaceutically acceptable salts thereof, as well as a use thereof for treating and / or preventing diseases or conditions related to abnormal expression of protein tyrosine phosphatase. The compounds are represented by formula (I).
Owner:HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTD

Trichoderma auritum GUWM22 and application thereof

ActiveCN120192855ABiocideFungiNicotiana tabacumPhomopsis sp.
The invention discloses a Trichoderma auritum GUWM22 strain and application thereof, and belongs to the field of microorganisms. The preservation number of the trichoderma auritum GUWM22 is CCTCC (China Center for Type Culture Collection) NO: M20242639, the preservation date is November 26, 2024, the preservation unit is China Center for Type Culture Collection, and the preservation address is Wuhan University, Wuhan, China. Experiments prove that the GUWM22 has a very strong inhibition effect on six pathogenic bacteria (phytophthora nicotianae, phytophthora capsici, botryosphaeria dothidea, alternaria alternata, phomopsis and colletotrichum capsici), the bacteriostasis rate reaches 78% or above, in addition, the GUWM22 also has a good prevention and treatment effect on anthracnose of picked peppers (line peppers), the prevention effect is 82.11%, and it can be seen that the GUWM22 can be used for preventing and treating anthracnose of the picked peppers (line peppers). The Trichoderma aureum GUWM22 is a new biocontrol Trichoderma strain with good potential. The invention provides a new strain resource and an environment-friendly and efficient biocontrol approach for effective prevention and treatment of pepper anthracnose.
Owner:GUIZHOU UNIV

Phytobacterium plantarum Lp116 with hypoglycemic capacity and application, product and method thereof

PendingCN119193391Alower blood lipid levelsAntibacterial agentsBacteriaBiotechnologyEscherichia coli
The invention relates to a plant lactobacillus with hypoglycemic ability, and an application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides a lactobacillus plantarum strain Lp116 with the capability of reducing blood sugar, and the preservation number of the lactobacillus plantarum strain Lp116 is CCTCC (China Center for Type Culture Collection) NO: M 20241784. The invention also provides an application of the strain Lp116 in preparation of hypoglycemic drugs or health-care foods with an auxiliary hypoglycemic function or bacteriostatic agents or non-treatment-destination bacteriostasis, and a product and a method based on the strain Lp116. The strain Lp116 disclosed by the invention has a relatively strong inhibition effect on escherichia coli, staphylococcus aureus, salmonella, streptococcus pharyngobuccal inflammation and streptococcus pseudopneumoniae, and can effectively achieve the effects of reducing blood sugar and regulating intestinal flora.
Owner:WUHAN WEIKANG PROBIOTICS RES INST CO LTD

Lactobacillus fermentum as well as compound preparation and application thereof

The invention provides lactobacillus fermentum as well as a compound preparation and application thereof, and relates to the technical field of microorganisms. Compared with a strain in the prior art, the lactobacillus fermentum HXJS4-1 disclosed by the invention has a better effect in the aspect of nucleoside degradation and can realize rapid nucleoside degradation. In addition, the compound has a stronger inhibition effect on xanthine oxidase, and the activity of the xanthine oxidase is effectively reduced. In mouse experiments, the strain also has an obvious uric acid reducing effect, also has a certain anti-inflammatory effect, can be used in the prevention and treatment process of hyperuricemia and gout, and provides a new probiotic or drug material for the treatment of hyperuricemia and gout. In addition, eating of the strain has no obvious influence on indexes of a sample body, and it is proved that the strain has the characteristic of high safety and can be widely applied to the fields of medicine and food.
Owner:BLOOMATURE BIOTECHNOLOGY CO LTD

Preparation method and application of Eupatorium chinense n-butyl alcohol effective part extract

The invention relates to a preparation method of an effective part extract of n-butyl alcohol of Eupatorium chinense and application of the effective part extract in treatment of diabetes complicated with depression. The technical scheme of the invention is to provide an extract of the n-butyl alcohol effective part of the eupatorium chinense, which can be used for treating diabetes complicated by depression diseases. In-vitro experiments show that the eupatorium chinense extract has an inhibition effect on acetylcholin esterase (AChE). In-vivo animal experiments find that classical anti-diabetes and depression treatment drugs, namely metformin hydrochloride and fluoxetine hydrochloride, are taken as positive controls, experimental research on the treatment effect of the effective part extract of the n-butyl alcohol of the eupatorium chinense on mice suffering from diabetes complicated with depression is developed, and research results show that the extract can regulate insulin resistance and can be used for treating diabetes complicated with depression. The glycometabolism of mice with diabetes mellitus complicated with depression is improved, and the depression symptom is improved. The extract has a remarkable effect of treating diabetes mellitus complicated with depression, has a good effect of treating diabetes mellitus complicated with depression, and is expected to be developed into a new natural medicine for treating diabetes mellitus complicated with depression.
Owner:CHINA THREE GORGES UNIV

Beta '-sulfo-alpha, beta-unsaturated gamma-lactam derivative as well as preparation method and application thereof

The invention provides a beta '-sulfo-alpha, beta-unsaturated gamma-lactam derivative as well as a preparation method and application thereof, and belongs to the technical field of organic chemical synthesis. The beta '-thio-alpha, beta-unsaturated gamma-lactam derivative has a structure as shown in a formula I. According to the method disclosed by the invention, cesium carbonate is taken as alkali, and a molecular skeleton of the beta'-thio-alpha, beta-unsaturated gamma-lactam derivative is constructed through free radical coupling and olefin isomerization processes under the condition of blue light irradiation. Bioactivity evaluation shows that the beta '-sulfo-alpha, beta-unsaturated gamma-lactam derivative prepared by the method disclosed by the invention has an inhibition effect on MDA-MB-231 human breast cancer cells.
Owner:MARINE MEDICAL RES INST OF GUANGDONG ZHANJIANG

Copper complex with anticancer activity and preparation method and application thereof

The invention belongs to the field of anti-cancer metal complexes, and particularly relates to a copper complex with anti-cancer activity and a preparation method and application thereof. Cu (OAc) 2H2O and coumarin-3-formyl-(2-aminomethylpyridine) are respectively dissolved in a solvent, the two solutions are mixed and stirred at room temperature to react for a period of time, the reaction solution is filtered, the filtrate is sealed and naturally volatilized at room temperature for 3-7 days, the complex can be obtained, the IC50 value of the complex to Hela cervical cancer cells is 0.8964 + / -0.09 mu M, and the IC50 value of the complex to Hela cervical cancer cells is 0.8964 + / -0.09 mu M. According to the present invention, the inhibition effect of the complex on HeLa cervical cancer cells is 3.38 times of the inhibition effect of cis-platinum, the toxicity of the complex on normal cells but HUVEC is very small, IC50 is greater than 100 [mu] M, and the complex has a high selectivity coefficient SI (SI = normal cell IC50 / cancer cell IC50), and the selectivity coefficient SI is greater than 111 and is 584 times of the selectivity coefficient of cis-platinum (SI = 0.19). The complex has the capability of inducing apoptosis of cancer cells and has concentration dependence. Meanwhile, the complex can retard cancer cells and an S phase so as to inhibit cell proliferation, and can generate an intercalation effect with HS-DNA (High-Speed Deoxyribose Nucleic Acid).
Owner:NANJING FORESTRY UNIV

Stratum corneum barrier function improving agent and pharmaceutical composition

The present invention addresses the problem of providing an improving agent for improving a stratum corneum barrier function without external replenishment with any moisturizing substance and a pharmaceutical composition containing said improving agent. The present invention provides: a stratum corneum barrier function improving agent which contains a glycolytic inhibitor as an active ingredient; the stratum corneum barrier function improving agent in which the glycolytic inhibitor is at least one selected from the group consisting of a glucose transporter inhibitor and a glucose competitive inhibitor; either of said stratum corneum barrier function improving agents having at least one selected from the group consisting of an inhibitory effect on the loss of skin moisture retention capacity and an inhibitory effect on skin permeability enhancement; and a pharmaceutical composition which contains any of said stratum corneum barrier function improving agents.
Owner:HAMAMATSU UNIV SCHOOL OF MEDICINE

Alkaloid compound in endophytic fungi of ferula sinkiangensis as well as preparation method and application of alkaloid compound

The invention relates to the technical field of ferula asafoetida endophytic fungi separation and purification, in particular to alkaloid compounds in ferula asafoetida endophytic fungi as well as a preparation method and application of the alkaloid compounds in the ferula asafoetida endophytic fungi. And extracting with dichloromethane to obtain dichloromethane part extract, and purifying and separating the dichloromethane part extract by adopting silica gel column chromatography and high performance liquid chromatography to obtain the alkaloid compounds in the endophytic fungi of ferula sinkiangensis. The alkaloid compound in the ferula sinkiangensis endophytic fungi is disclosed for the first time, the compound is subjected to an in-vitro anti-tumor pharmacodynamic experiment, and according to the experiment result, the alkaloid compound has a certain inhibition effect on MCF-7 cells; therefore, the alkaloid compound can be used for preparing the medicine for preventing and treating the breast cancer, and a new medicine is provided for preventing and treating the breast cancer.
Owner:XINJIANG UYGUR AUTONOMOUS REGION INST OF TRADITIONAL CHINESE MEDICINE & ETHNIC MEDICINE

Dual-targeting carrier material, preparation method thereof and preparation method of oleanolic acid nanoparticles wrapped by dual-targeting carrier material

The invention provides a dual-targeting carrier material, a preparation method thereof and a preparation method of oleanolic acid nanoparticles wrapped by the dual-targeting carrier material, and belongs to the technical field of medicines. The oleanolic acid targeting nanoparticles are prepared by taking a dual-targeting high-molecular copolymer as a carrier material and adopting an emulsification-solvent evaporation method, so that the oleanolic acid can be protected from being quickly degraded, and the in-vivo circulation time of the oleanolic acid can be prolonged. Meanwhile, targeted delivery of oleanolic acid is realized through a targeted group, the concentration of the drug in tumor tissues is improved, and toxic and side effects on normal tissues are reduced. An MTT method is adopted, the inhibition effect of the oleanolic acid nanoparticles on cell growth is researched, and the result shows that the oleanolic acid targeting nanoparticles have a stronger effect of inhibiting tumor cell proliferation compared with an oleanolic acid raw material medicine.
Owner:HUBEI UNIV OF SCI & TECH

Cryptosporidium-resistant small-molecule lead compound targeting cryptosporidium helicase

ActiveCN119351519AOrganic active ingredientsMicrobiological testing/measurementCryptosporidium infectionCryptosporidium parvum
The invention relates to an anti-cryptosporidium micromolecular lead compound of a target cryptosporidium helicase. Comprising the following steps: S1, detecting enzyme activity parameters of a drug target helicase (CpeIF4A) and an inhibition effect of Roc-A on the drug target helicase: expressing and purifying a CpeIF4A recombinant protein containing an MBP tag; detecting the enzyme activity; detecting the inhibition effect of the Roc-A on the enzyme activity; determining the affinity between the Roc-A and the CpeIF4A through a heat transfer experiment; s2, in-vitro drug effect determination: evaluating the direct killing capability of Roc-A on sporozoites; the inhibition effect of Roc-A on cryptosporidium is determined through an in-vitro cell infection model, an EC50 value is obtained, and the intracellular period of the Roc-A mainly playing the inhibition effect is determined; detecting the toxicity of Roc-A to host cells to obtain a TC5 value), and obtaining an in-vitro insect-resistant selectivity index (SI); and S3, in-vivo drug effect test: establishing a C57BL / 6IFN-gamma gene knockout mouse infection model to evaluate the effectiveness and safety of Roc-A. The invention determines that the Roc-A has the potential of being further developed into the cryptosporidium-resistant drug, and verifies that the targeted eIF4A can resist cryptosporidium infection.
Owner:JILIN UNIVERSITY

Yak-derived Lactobacillus reuteri with anti-oxidation, anti-inflammatory and anti-hypoxia capabilities and application of Lactobacillus reuteri

The invention discloses lactobacillus reuteri with antioxidant, anti-inflammatory and anti-hypoxia capabilities, the name of the lactobacillus reuteri is QM11, the classification name of the lactobacillus reuteri is CGMCC NO.31541, the preservation number of the lactobacillus reuteri is CGMCC NO.31541, the preservation date of the lactobacillus reuteri is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing on August 5, 2024, and the preservation number of the lactobacillus reuteri is CGMCC NO.31541, the preservation number of the lactobacillus reuteri is CGMCC NO.31541, the preservation number of the lactobacillus reuteri is CGMCC NO.31541, and the preservation number of the lactobacillus reuteri is CGMCC NO.31541. The preservation unit is China General Microbiological Culture Collection Center (CGMCC). The lactobacillus reuteri is separated from faeces of healthy yaks in Qinghai province, has relatively strong acid and cholate tolerance, has relatively good antioxidant and anti-inflammatory capacities, and has a relatively strong inhibition effect on pathogenic bacteria such as yak-derived pathogenic escherichia coli, staphylococcus aureus and salmonella typhimurium; the sodium dextran sulfate induced mouse colitis symptom is relieved, and the hypoxia tolerance of the mouse is improved. The lactobacillus reuteri disclosed by the invention can be used for preparing medicines or microecological preparations for resisting oxidation, inflammation and hypoxia, and has a very wide application prospect.
Owner:TIANJIN UNIV OF SCI & TECH +1

A broad-spectrum antibacterial peptide, its preparation method and application

The present invention discloses a broad-spectrum antibacterial peptide, and the amino acid sequence of the antibacterial peptide is GECEGNNRPVKKPQPRKKLPRFKKC-NH2. Based on melittin, the present invention designs antibacterial peptides by predicting based on a deep learning model, and obtains antibacterial peptides with broad-spectrum bacteriostasis, thermal stability and low hemolytic property, which have good inhibitory effects on skin pathogenic bacteria such as Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans and Propionibacterium acnes. Peptides predicted as AMP amino acid sequences by the deep learning model antibacterial peptide prediction tool amPEPpy are selected for screening, and by using a biosynthesis technique, they are expressed, extracted and purified in Escherichia coli, reducing the workload and screening period of screening, and increasing the probability of screening out broad-spectrum and thermally stable biosynthetic antibacterial peptides.
Owner:GUANGZHOU RIDGEPOLE BIOLOGICAL TECH CO LTD +1

Aromatic fused ring compound, pharmaceutical composition containing aromatic fused ring compound and application of aromatic fused ring compound

The invention provides an aromatic fused ring compound, a pharmaceutical composition containing the compound and application of the aromatic fused ring compound, and relates to the technical field of medicines. The aromatic fused ring compound disclosed by the invention has a structure as shown in a formula (I): # imgabs0 # or a stereoisomer and pharmaceutically acceptable salt thereof, wherein the structural unit # imgabs1 # is selected from # imgabs2 # or # imgabs3 #, and each substituent group is defined in the specification. The aromatic fused ring compound has a strong inhibition effect on SIKs enzyme activity, has a positive regulation effect on TNF-alpha and IL-10 in serum of mice with acute inflammation, has a longer half-life period and a higher oral exposure amount, has a remarkable inhibition effect on NF-kappa B gene expression of THP-1 cells under MDP stimulation, and can be used for preparing medicines for treating acute inflammation. The traditional Chinese medicine composition has a remarkable weight recovery promoting effect on cachexia induced by cis-platinum.
Owner:HANG ZHOU YUHONG PHARMATECH CO LTD

Short peptide from undaria pinnatifida and application thereof

The invention discloses an oligopeptide from undaria pinnatifida and application thereof. The amino acid sequence of the oligopeptide is YRKD, and the molecular weight is 580.63 g / mol. The polypeptide is identified from undaria pinnatifida through a high performance liquid chromatography technology for the first time, and an unreported oligopeptide capable of inhibiting tyrosinase and cooperating with vitamin C to synergistically inhibit tyrosinase is screened out. The oligopeptide derived from undaria pinnatifida is synthesized by a solid phase method, has the characteristics of safety, no toxicity, good water solubility and good stability, and is combined with vitamin C to generate a synergistic effect and synergistically increase the inhibition effect on tyrosinase, so that the oligopeptide can achieve a better tyrosinase inhibition effect at a lower and more stable concentration; the use concentration of the oligopeptide can be greatly reduced, the stability is enhanced, and the oligopeptide can be widely applied to preparation of cosmetics, medicines, health-care products or food additives, and has important economic value and social significance.
Owner:GUANGZHOU TAIWEI FEED CO LTD